Combined celecoxib and epirubicin therapy potently suppressed the neovascularization, hepatic CSC marker CD44/CD133, and MDR‐1 drug pump expression in Novikoff hepatoma tissues. The gene discussed is PROM1; the disease is hepatocellular carcinoma.